BMY (bristol myers squibb) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BMY (bristol myers squibb)

BMY 46.02

-0.1%

Nov 3 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: MrGreenJeans who wrote (60)	3/28/1999 6:49:00 PM
From: LABMAN	of 194

LATEST HEADLINE Home - Yahoo! - Help [ Business \| US Market \| By Industry \| IPO \| AP \| S&P \| International \| PRNews \| BizWire ] Sunday March 28, 6:17 pm Eastern Time Bristol-Myers holds comment on Glaxo interest NEW YORK, March 28 (Reuters) - Bristol-Myers Squibb Co. (NYSE:BMY - news) declined to comment Sunday on reports that Britain's Glaxo Wellcome Plc (quote from Yahoo! UK & Ireland: GLXO.L) is interested in acquiring the U.S. drug copmany. ''We don't comment on rumors,'' spokeswoman Peggy Ballman told Reuters. Several UK newspapers reported on Sunday that Glaxo had held talks with Bristol-Myers on a potential merger, but that talks had stalled. Glaxo also previously declined to comment on the reports. More Quotes and News: Bristol-Myers Squibb Co (NYSE:BMY - news) Related News Categories: health, options, US Market News Help Copyright © 1999 Reuters Limited. All rights reserved. Republication or redistribution of Reuters content is expressly prohibited without the prior written consent of Reuters. Reuters shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. See our Important Disclaimers and Legal Information. Questions or Comments?

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next